Premium
Lipid profiles for nevirapine vs . atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment‐naïve HIV‐1‐infected patients (the ARTEN study)
Author(s) -
Podzamczer D,
AndradeVillanueva J,
Clotet B,
Taylor S,
Rockstroh JK,
Reiss P,
Domingo P,
Gellermann HJ,
de Rossi L,
Cairns V,
Soriano V
Publication year - 2011
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/j.1468-1293.2011.00917.x
Subject(s) - nevirapine , ritonavir , emtricitabine , atazanavir , medicine , apolipoprotein b , apolipoprotein a1 , lopinavir , gastroenterology , cholesterol , pharmacology , triglyceride , human immunodeficiency virus (hiv) , endocrinology , viral load , virology , antiretroviral therapy
Objectives Dyslipidaemic effects of antiretrovirals (ARVs) may contribute to increased cardiovascular risk (CR) in HIV‐1‐infected patients. The ARTEN (atazanavir/ritonavir on a background of tenofovir and emtricitabine vs . nevirapine on the same background, in naïve HIV‐1‐infected patients) study compared prospectively ritonavir‐boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed‐dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV‐naïve HIV‐1‐infected patients. Lipid profiles and CR from baseline to week 48 are reported. Methods Changes from baseline to week 48 in fasting plasma levels of total cholesterol (TC), high‐density lipoprotein cholesterol (HDL‐c), low‐density lipoprotein cholesterol (LDL‐c), TC:HDL‐c ratio, apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB) and total triglycerides (TG) were determined. The Framingham algorithm was used to estimate CR. Analysis was by intention‐to‐treat (ITT) with last observation carried forward (LOCF) for missing data. Results At week 48, NVP treatment resulted in significantly greater mean increases from baseline in TC (24.4 vs. 19.6 mg/dL; P =0.038), HDL‐c (9.7 vs . 3.9 mg/dL; P <0.0001), LDL‐c (15.0 vs . 10.4 mg/dL; P =0.011) and ApoA1 (0.18 vs . 0.08 g/L; P <0.0001) but not ApoB (0.02 vs . 0.02 g/L) compared with ATZ/r treatment. ATZ/r use was associated with higher mean TG increases (27.80 vs . 0.02 mg/dL; P =0.0001). Significantly greater mean decreases in TC:HDL‐c and ApoB/ApoA ratios were observed with NVP vs . ATZ/r ( P =0.0001 and P =0.008, respectively). Framingham CR scores were low and comparable between the arms, with only a slight mean increase from baseline to week 48 of 0.70 for NVP and 0.80 for ATZ/r [difference −0.069; 95% confidence interval (CI) −0.61 to 0.46; P =0.80]. Conclusions In ARV‐naïve patients with low CR at the outset, NVP showed a potentially less atherogenic lipid profile compared with ATZ/r.